Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERNA Ernexa Therapeutics	$1.56 -9.8%	$2.29	$1.53 ▼ $29.25	$12.74M	5.3	86,702 shs	54,669 shs
EVAX Evaxion A/S	$2.61 -2.6%	$2.58	$1.20 ▼ $17.75	$3.76M	0.13	117,826 shs	70,477 shs
LPTX Leap Therapeutics	$0.31 -1.3%	$0.35	$0.22 ▼ $4.79	$12.85M	-0.27	331,448 shs	213,029 shs
PMN Promis Neurosciences	$0.77 -0.6%	$0.56	$0.38 ▼ $1.59	$25.21M	-0.05	21.42 million shs	582,691 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERNA Ernexa Therapeutics	-9.83%	-20.00%	-21.21%	-48.64%	-94.25%
EVAX Evaxion A/S	-2.61%	-4.04%	+5.67%	+66.24%	-81.75%
LPTX Leap Therapeutics	-1.29%	-14.93%	+6.25%	-27.19%	-85.70%
PMN Promis Neurosciences	-0.60%	-22.30%	+71.09%	+19.77%	-46.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERNA Ernexa Therapeutics	0.8369 of 5 stars	0.0	5.0	1.1	1.7	0.0
EVAX Evaxion A/S	1.8577 of 5 stars	3.5	2.0	1.8	1.7	0.0
LPTX Leap Therapeutics	1.8868 of 5 stars	3.0	4.0	0.6	0.0	1.3
PMN Promis Neurosciences	2.3666 of 5 stars	3.5	2.0	3.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERNA Ernexa Therapeutics	0.00	N/A	N/A	N/A
EVAX Evaxion A/S	3.00	Buy	$10.00	283.14% Upside
LPTX Leap Therapeutics	2.00	Hold	$3.38	1,002.94% Upside
PMN Promis Neurosciences	3.00	Buy	$4.33	465.34% Upside

Current Analyst Ratings Breakdown

Latest EVAX, ERNA, PMN, and LPTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	PMN Promis Neurosciences	Leede Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/12/2025	PMN Promis Neurosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERNA Ernexa Therapeutics	$535K	21.48	N/A	N/A	$0.50 per share	3.12
EVAX Evaxion A/S	$3.34M	1.09	N/A	N/A	($1.18) per share	-2.21
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$0.91 per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	$0.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERNA Ernexa Therapeutics	-$44.54M	-$8.31	N/A	∞	N/A	-7,652.75%	N/A	-285.71%	8/12/2025 (Estimated)
EVAX Evaxion A/S	-$10.57M	-$1.16	N/A	N/A	N/A	-316.03%	-532.72%	-78.32%	8/13/2025 (Estimated)
LPTX Leap Therapeutics	-$67.56M	-$1.70	N/A	N/A	N/A	N/A	-162.15%	-120.05%	8/11/2025 (Estimated)
PMN Promis Neurosciences	$2.78M	-$0.05	N/A	N/A	N/A	N/A	-186.19%	-98.56%	8/6/2025 (Estimated)

Latest EVAX, ERNA, PMN, and LPTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	EVAX Evaxion A/S	-$0.50	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	LPTX Leap Therapeutics	-$0.29	N/A	N/A	N/A	N/A	N/A
5/27/2025	Q1 2025	EVAX Evaxion A/S	-$0.65	-$0.29	+$0.36	-$0.29	$0.06 million	N/A
5/13/2025	Q1 2025	LPTX Leap Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	N/A	N/A
5/12/2025	Q1 2025	PMN Promis Neurosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
EVAX Evaxion A/S	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERNA Ernexa Therapeutics	N/A	0.21	0.21
EVAX Evaxion A/S	N/A	2.01	2.01
LPTX Leap Therapeutics	N/A	2.41	2.41
PMN Promis Neurosciences	N/A	3.36	3.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERNA Ernexa Therapeutics	70.55%
EVAX Evaxion A/S	11.04%
LPTX Leap Therapeutics	30.46%
PMN Promis Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
ERNA Ernexa Therapeutics	1.50%
EVAX Evaxion A/S	41.64%
LPTX Leap Therapeutics	7.50%
PMN Promis Neurosciences	6.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERNA Ernexa Therapeutics	10	7.37 million	7.26 million	No Data
EVAX Evaxion A/S	60	1.40 million	819,000	No Data
LPTX Leap Therapeutics	40	41.44 million	38.33 million	Optionable
PMN Promis Neurosciences	5	32.69 million	30.69 million	Not Optionable

EVAX, ERNA, PMN, and LPTX Headlines

Recent News About These Companies

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

July 29, 2025 | globenewswire.com

ProMIS Neurosciences Announces Private Placement Financing

July 28, 2025 | globenewswire.com

Analysts Set Expectations for PMN FY2025 Earnings

July 25, 2025 | americanbankingnews.com

ProMIS Neurosciences Announces Private Placement Financing

July 22, 2025 | globenewswire.com

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

July 21, 2025 | globenewswire.com

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

July 21, 2025 | globenewswire.com

HC Wainwright & Co. Initiates Coverage of ProMIS Neurosciences (PMN) with Buy Recommendation

July 15, 2025 | msn.com

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 17, 2025 | globenewswire.com

ProMIS Neurosciences Inc. Announces Completion of First Cohort in PRECISE-AD Trial for PMN310 in Alzheimer's Disease

May 13, 2025 | nasdaq.com

ProMIS Neurosciences Stock Price, Quotes and Forecasts | NASDAQ:PMN | Benzinga

May 13, 2025 | benzinga.com

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025 | globenewswire.com

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year

March 31, 2025 | markets.businessinsider.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025 | finanznachrichten.de

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025 | globenewswire.com

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

March 24, 2025 | globenewswire.com

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

March 13, 2025 | globenewswire.com

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

March 11, 2025 | globenewswire.com

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

February 25, 2025 | markets.businessinsider.com

ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial

February 25, 2025 | markets.businessinsider.com

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

February 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term
By Leo Miller | July 22, 2025
View Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term
CSX Stock Rally: Strong Options Flow, Analyst Price Targets
By Jeffrey Neal Johnson | July 18, 2025
View CSX Stock Rally: Strong Options Flow, Analyst Price Targets
3 Retailers Poised to Outmaneuver Tariff and Recession Concerns
By Nathan Reiff | July 20, 2025
View 3 Retailers Poised to Outmaneuver Tariff and Recession Concerns

EVAX, ERNA, PMN, and LPTX Company Descriptions

Ernexa Therapeutics NASDAQ:ERNA

$1.56 -0.17 (-9.83%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.62 +0.06 (+3.85%)

As of 08/1/2025 07:23 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Evaxion A/S NASDAQ:EVAX

$2.61 -0.07 (-2.61%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.60 0.00 (-0.19%)

As of 08/1/2025 05:18 PM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Leap Therapeutics NASDAQ:LPTX

$0.31 0.00 (-1.29%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.31 0.00 (0.00%)

As of 08/1/2025 06:33 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Promis Neurosciences NASDAQ:PMN

$0.77 0.00 (-0.60%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.76 -0.01 (-0.72%)

As of 08/1/2025 07:53 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time